Pro-Dex (NASDAQ:PDEX) CEO Kirk Richard Lee Van, Jr. Sells 765 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) CEO Kirk Richard Lee Van, Jr. sold 765 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $59.36, for a total transaction of $45,410.40. Following the completion of the transaction, the chief executive officer directly owned 79,228 shares in the company, valued at $4,702,974.08. This trade represents a 0.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pro-Dex Stock Up 6.0%

Shares of NASDAQ:PDEX opened at $66.56 on Tuesday. The business has a fifty day moving average of $62.51 and a two-hundred day moving average of $58.01. The company has a quick ratio of 2.45, a current ratio of 4.10 and a debt-to-equity ratio of 0.28. The stock has a market cap of $212.99 million, a P/E ratio of 16.12 and a beta of 0.06. Pro-Dex, Inc. has a 52-week low of $23.47 and a 52-week high of $77.00.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings data on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.20. Pro-Dex had a net margin of 17.62% and a return on equity of 25.13%. The firm had revenue of $20.40 million during the quarter, compared to analyst estimates of $19.20 million. On average, research analysts expect that Pro-Dex, Inc. will post 2.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Pro-Dex from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Ascendiant Capital Markets boosted their target price on Pro-Dex from $70.00 to $74.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings upgraded Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, September 4th. Finally, Zacks Research upgraded Pro-Dex to a “hold” rating in a research report on Tuesday, May 19th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $74.00.

Hedge Funds Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PDEX. California State Teachers Retirement System purchased a new stake in shares of Pro-Dex during the second quarter worth $99,000. Navellier & Associates Inc. purchased a new position in Pro-Dex in the second quarter valued at $322,000. Morgan Dempsey Capital Management LLC grew its stake in Pro-Dex by 6.2% during the 1st quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier’s stock worth $286,000 after purchasing an additional 339 shares in the last quarter. Corsair Capital Management L.P. purchased a new stake in Pro-Dex during the 1st quarter worth about $532,000. Finally, Bank of New York Mellon Corp acquired a new stake in Pro-Dex in the 2nd quarter valued at about $678,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.